The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The company will market it under the brand name Molflu
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The Home Healthcare market is expected to be US $ 14.2 by 2025
This product will be manufactured at Lupin's Goa facility in India
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Subscribe To Our Newsletter & Stay Updated
